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Background: The advantages of patient-held portable health files (PHF) and personal health records (PHR), paper or
electronic, are said to include improved health-care provider continuity-of-care and patient empowerment in maintaining
health. Top-down approaches are favored by public sector government and health managers. Bottom-up approaches
include systems developed directly by health-care providers, consumers and industry, implemented locally on devices
carried by patient-consumers or shared via web-based portals. These allow individuals to access, manage and share
their health information, and that of others for whom they are authorized, in a private, secure and confidential
environment. Few medical record technologies have been evaluated in randomized trials to determine whether
there are important clinical benefits of these interventions. The COMMUNICATE trial will assess the acceptability and
long-term clinical outcomes of an electronic and paper patient-held PHF.
Methods/Design: This is a 48-month, open-label pragmatic, superiority, parallel-group design randomized controlled
trial. Subjects (n=792) will be randomized in a 1:1:1 ratio to each of the trial arms: the electronic PHF added to usual
care, the paper PHF added to usual care and usual care alone (no PHF). Inclusion criteria include those 60 years or older
living independently in the community, but who have two or more chronic medical conditions that require prescription
medication and regular care by at least three medical practitioners (general and specialist care). The primary objective is
whether use of a PHF compared to usual care reduces a combined endpoint of deaths, overnight hospitalizations and
blindly adjudicated serious out-of-hospital events. All primary analyses will be undertaken masked to randomized arm
allocation using intention-to-treat principles. Secondary outcomes include quality of life and health literacy improvements.
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Discussion: Lack of blinding creates potential for bias in trial conduct and ascertainment of clinical outcomes. Mechanisms
are provided to reduce bias, including balanced study contact with all participants, a blinded adjudication committee
determining which out-of-hospital events are serious and endpoints that are objective (overnight hospitalizations and
mortality). The PRECIS tool provides a summary of the trial’s design on the Pragmatic-Explanatory Continuum.
Trial registration: Registered with Clinicaltrials.gov (identifier: NCT01082978) on 8 March 2010.
Keywords: Personal health records, Electronic medical records, Health information technology, Randomized
controlled trial, Pragmatic trial, Medical decision making, Medical informatics, Health services researchBackground
The advantages of patient-held portable health files
(PHF) and personal health records (PHR) have been dis-
cussed in the medical literature for many years [1–4],
and include improved continuity of care, improved pa-
tient understanding of instructions and encouragement
for patients to take an active role in maintaining their
health. In one outpatient service the primary determi-
nants of patient-held paper PHF (p-PHF) acceptance
and use were physicians’ support of the process and ac-
tual size of the record, that is, the smaller the better [1].
Although there are some practical problems and ethical
arguments for and against the use of patient-held re-
cords (ownership, privacy and confidentiality), research
indicates that there are no substantial practical draw-
backs, and that there are considerable ethical benefits
to be derived from some form of shared record-keeping
[2, 5–7]. Patients mostly perceive the PHR as a personal
document for reference, while GPs perceive it as a man-
agement and communication tool [3].
Different types of paper-based patient-held records
have been considered, including full copies of patient
files, extracted summaries and censored summaries.
In the era of information technology, new electronic
computer-based applications for medical records have
been developed and have enabled patient-held PHFs to
be electronic-based. Patient-centered recording with use
of medical data to promote effective clinical communi-
cation and cooperative care is considered one important
goal [8–10]. Standards and practices are required to pro-
vide a framework for electronic patient-centered health
care, with appropriate regulations for the storage and
exchange of health-care data and a greater emphasis on
professional information management skills. Two other
important goals are process-integrated decision sup-
port integrated directly into systems to access current
medical evidence resources, and comprehensive easily
retrievable patient data for research and health-care
reporting. If these can be combined with an effective
and acceptable form of patient-centered recording, one
would anticipate that with time, health-care outcomes
would improve and costs would decrease.Several models of patient-centered electronic health
records have been developed. Top-down approaches are
favored, particularly by public sector government and
health managers. One approach involves a networked
environment and unique patient and provider identifiers.
In Australia, this approach included the Health Connect
project (1999 to 2004) [11], which was not successfully
implemented but was followed by the establishment of
the National E-Health Transition Authority (NEHTA) in
late 2004 [12]. One of NEHTA’s tasks was to develop
standards to ensure consistent and accurate ways of
electronically collecting and securely exchanging health
information. This would allow medical data information
exchange as well as a means for health-care research
and for health statistics.
In a national approach to electronic health records,
the electronic health record is seen as a tool for provi-
ding person-centered health care safely and efficiently in
the modern information environment. The costs asso-
ciated with the introduction of a national system are
considerable. One overarching issue is the trade-off bet-
ween ease of (appropriate) access and security. Inter-
operability, the ability to transfer and use information in
a uniform and efficient manner across multiple organi-
zations and information technology systems, is critical.
An interoperability framework is a reference point for
both existing and new e-health stakeholders, including
planners concerned with the enabling role of technology
in the delivery of health-care services, clinical informa-
tics experts concerned with the meaning of information,
enterprise and solution architects, as well as the pro-
viders and recipients of health care.
In 2009 another top-down approach was recommended
by the Australian National Health and Hospitals Reform
Commission: the Personally Controlled Electronic Health
Record (PCEHR) system. The PCEHR is meant to be a se-
cure electronic record of medical information that is
stored and shared in a network of connected systems.
Every Australian resident has been allocated a unique na-
tional identifier and every registered health-care provider
has been allocated a unique national health-care provider
identifier. Vendors are developing products that can
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not yet fully operational, and ethics and privacy concerns
remain [13, 14]. Although launched in 2012, problems
with roll-out and lack of meaningful use led to a review
published in May 2014, which suggested extensive
changes to the program [15].
Other approaches include systems developed by pro-
viders, consumers and industries that have developed
local portals of patient-held or patient-controlled PHFs
or PHRs. These are electronic applications through
which individuals can access, manage and share their
health information, and that of others for whom they are
authorized, in a private, secure and confidential envi-
ronment. Models of PHRs include stand-alone systems
or systems integrated with health provider electronic
medical records, PHRs carried on smart cards, on CD
ROMS and more recently, on USB flash drives, or PHRs
accessed through a secure web-based portal [16–18].
Web-based and other uploaded applications have been
developed that allow patients to enter their own in-
formation into secure PHRs. International examples in-
clude HealthSpace, a website set up by the UK NHS
[19], which closed operations in December 2012, and from
industry [20], Google Health [21] (which discontinued its
operations in 2011 and all data is being systematically
deleted), and Microsoft HealthVault [22] and Dossia
[23], both of which are still operating. The latter two
either primarily target healthy and well-educated con-
sumers or are directly linked to employer organizations
or Health Maintenance Organizations (HMO), rather
than being a tool for chronic disease management in pa-
tients with multiple co-morbidities. These web-based
systems were promoted as a means of providing patients
and providers with universal access to updated medical
information. Most PHRs are not designed to be the pri-
mary record of the health-care system, but a prospective
extract of core medical information (such as medical
conditions, medications, results of investigations and
procedures). Some systems are free and open source and
claim to meet policy requirements of data encryption, se-
cure access, authentication and authorization. One review
of web-based systems reported limited functionality [18].
Whether top down or bottom up, the challenges in
establishing IT systems in health care are many, in-
cluding technical hurdles, administrative needs, legal
requirements and resistance and/or inertia from a
commitment to existing systems. The entire under-
taking is predicated on an assumption of meaningful
added-value attributed to the IT system compared to
conventional systems. Testing this assumption and
quantifying benefit are critical stages in the develop-
ment of an IT system, and proof-of-concept during
development will play a key role in either stimulating
or discouraging further work.Formal scientific assessments of added-value of
electronic medical record support systems are often
conducted in small networks of group practices, in
a large single hospital or similar health-care organi-
zation and assess process outcomes such as degree of
acceptability or satisfaction [24, 25]. Some support
systems have documented reductions in mortality in
before-after non-randomized settings [26]. Although
such process assessments are important and necessary
steps, and non-randomized assessments of interven-
tions are important, an IT system with documented
benefits in patient-relevant health outcomes in a ran-
domized design would have a much stronger case for
broad usage. There are randomized controlled trials in
this setting [27–30]. Two randomized trials attempted to
demonstrate benefit in short-term clinical outcomes, qual-
ity of life in oncology and symptoms scores in schizophre-
nia. Neither was successful, although both were arguably
underpowered. Importantly, it was difficult finding reports
of randomized trials of an IT health-care support system
measuring important long-term outcomes of health care.
One study in Australia that encompassed a variety of
process measures failed to show differences comparing a
computer-generated PHR with conventional records [27].
In 2005 we set out to evaluate a patient-held PHF car-
ried by the patient on a USB flash drive. The pilot study
design was a prospective non-randomized trial in pa-
tients with rheumatoid arthritis. The method of patient
allocation to PHF was as follows: the first 25 % of re-
cruited patients were allocated to no PHF (control
group), the second 25 % were allocated to New South
Wales (NSW) Health My Health Record, the third 25 %
were allocated to p-PHF and the fourth 25 % were allo-
cated to electronic PHF (e-PHF). Non-randomized allo-
cation was conducted for this pilot because PHF
development and availability varied, the project timeline
was short (funding was available for only nine months)
and because not all GPs had access to or used a com-
puter. Patients of GPs without computers were not allo-
cated to e-PHF. Halfway through the project patients in
the no PHF arm were allocated to either p-PHF or
e-PHF [31]. Both the newly designed paper-based and
electronic files contained a core data set of information
that included a directory of health-care providers, medi-
cal conditions, medications (current and past), investiga-
tions and visit summaries. This core data functioned as
a subset of a more comprehensive electronic or paper-
based medical record. It was structured to be patient
and doctor-friendly and was not primarily a physician
record. The PHF was updated by the doctor at each visit
and could also be updated by patient between visits.
The e-PHF included audit information for each modifi-
cation, including the computer host and login name iden-
tification of the doctor and visit date. The combination
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tient data, and user’s ordinary authentication via the host
computer operating system. The patient information was
stored as separate files for each patient in the form of xml
files encoded using a standard compression algorithm.
Hardware and software were inexpensive and mainten-
ance costs were small. The USB flash drive was robust,
fast and stored large data files as well as all required soft-
ware. The electronic file, an XML standard document,
could import and export specified data, thereby reducing
duplicate data entry, minimizing workflow interruption
and facilitating synchronization [32]. Quantitative and
qualitative methods were used in the evaluation of the
project’s outcomes. This project was funded by the Com-
monwealth of Australia, Australian Musculoskeletal Qual-
ity Improvement Project.
In this pilot study, a consecutive sample of 105 patients
with rheumatoid arthritis from three rheumatologists were
asked to participate over a four-month-period, and
nearly 80 % agreed after discussion with family and their
GPs. The final sample was 76 patients, the average age
was 63 years and the majority were female (78 %) and
were born in Australian (74 %). The final GP sample size
was 62. The study showed that the use of a patient-held
PHF improved health-provider communication, patient
and practitioner satisfaction and increased implementa-
tion of core set of quality indicators in arthritis [31].
Seven focus groups were also held, consisting of 43 pa-
tients and 12 GPs. Privacy and acceptability by both pa-
tients and health-care providers were evaluated in these
focus groups and using self-report questionnaires. About
10 % of GPs did not wish to participate in the trial, some
dissuading their patients from continuing, citing concerns
regarding privacy and confidentiality. Most of these GPs
had practices outside the catchment area of the health ser-
vice that was conducting the project. Otherwise, the results
were very encouraging [33]. A total of 80 % of patients
would recommend a PHF to others, almost all liked to idea
of carrying their own health data using a PHF and about
half added information to the PHF. A minority (about
13 %) were often or sometimes concerned about privacy.
Patients mostly perceived the PHF as a means of carrying
information between health-care providers, and the major-
ity of GPs said they would use it in the future [31].
In this pilot study we evaluated proof-of-concept
practicalities that would be encountered in random-
ized controlled trial in Australia, including success of
recruitment procedures, feasibility of subject compli-
ance with tools and assessments, quality of the data
collection forms and use in sample size estimations.
We used this knowledge to design a larger rando-
mized controlled trial of a paper and electronic-based
patient-held PHF across all patient disease groups. The
COMMUNICATE trial will assess the acceptability andlong-term outcomes resulting from the usage of e-PHFs
(carried by the patient on a USB flash drive) and p-PHFs
in a population with high intensity use of medical services.
The rationale is that use of PHFs provides a conduit of
direct communication among health-care providers of im-
portant health-care information, and that this leads to bet-
ter care and patient outcomes.
Methods/Design
Aims and objectives
This is a three-arm, randomized controlled trial that com-
pares usual care (no PHF) to two patient-held PHFs: an
e-PHF carried on a USB flash drive, and a p-PHF, in pa-
tients that are 60 years or older and who have two or
more chronic medical conditions (see Inclusion criteria).
The primary objective is to determine whether use of a
PHF compared to usual care, over 48 months, reduces a
combined endpoint of deaths, overnight hospitalizations
and serious out-of-hospital events.
The secondary objectives are to determine whether
use of a PHF over 48 months compared to usual care
improves quality of life as measured by the EQ-5D [34,
35], and health status as measured by the Short-Form
Health Survey SF-36 [36], and whether PHFs are accept-
able in terms of user-friendliness, convenience and use-
fulness to patients and their health-care providers.
Additional objectives are to determine whether use of
a PHF over four years compared to usual care improves
delivery, quality and efficiency of health care by im-
proved health literacy, reduction in medication errors,
reduction in duplicative investigations, improved adher-
ence to management plans, reduced health-care utilization
and reduced costs.
The assigned intervention (e-PHF, p-PHF or no PHF)
will be used for 48 months. Patients will also be followed
up on for an additional 36 months beyond the conclu-
sion of the randomized trial. This protocol is reported in
accord with the Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) 2013 guidance
for protocols in clinical trials [37].
Methods: participants, interventions and outcomes
Design and setting
This single-center pragmatic study is an open-label, ran-
domized, parallel-group design. Patients will be random-
ized in a 1:1:1 ratio to each of the trial arms: the e-PHF
added to usual care, the p-PHF added to usual care and
usual care alone (no PHF). This is a 48-month trial and
the assigned treatment (e-PHF or p-PHF) will be used
for 48 months. Patients will also be followed up on for
an additional 36 months beyond the conclusion of the
randomized component of the trial. Patient trial data
collection begins at three months post allocation of their
intervention, and continues every six months until
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lection is collected. Following this trial subjects are moni-
tored at annual intervals for a further 36 months (Fig. 1).
The trial is conducted in the suburban regions of St
George and Sutherland in southern Sydney, Australia.
Selection of patients
The trial population is enriched with patients who are
high-intensity users of health care.
Inclusion criteria
Demographic
1. Subjects must be of age 60 or greater.
2. Subjects living independently in the community;
hostel care is acceptable, but patients that are not
independent, that is, requiring full nursing home
care are excluded.Fig. 1 Flow diagram: the COMMUNICATE trialIntensity of medical care
3. Subjects must have had six medical practitioner
visits in the previous 12 months.
4. Subjects must have at least two of the following
confirmed chronic diseases that require prescription
oral or parenteral drug treatment or surgery, and
require at least annual specialist consultation:
cardiovascular, respiratory, endocrine, renal,
neurologic, gastrointestinal, hepatic, genitourinary,
hematologic, infectious, rheumatic, inflammatory,
immunologic or neoplastic diseases.
Computer resources of GP and of specialists
6. Subject’s GP must have access to a computer
with a Windows operating system during the
consultation visit.
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specialists, at least one of whom has access to a
computer during the consultation visit.
Ethical
8. Subjects must be able to understand the purpose of
the trial and provide full and valid informed consent.
Exclusion criteria
Medical
1. Subjects with a life expectancy of less than 12 months.
Other
2. Subjects who are unable to carry a p-PHF or e-PHF
and have no caregiver willing and able to do this on
their behalf.
3. Subjects who are mentally unable to provide valid
informed consent.
4. Subjects who are not independent in the community,
that cannot mobilise to see a health-care provider or
require full nursing home care.
Subject recruitment
Health-care providers will be contacted directly about the
trial, and patient information brochures and posters will be
provided in practice waiting rooms, hospital wards, out-
patient clinics and local community groups. There will also
be information sessions through specialist societies, divi-
sions of general practice and through the local media.
Several methods of subject recruitment will be used to
ensure that patients who are high users of health services
participate: recruitment from health provider practices,
both general practice and specialist practice, and recruit-
ment from inpatients at St George and Sutherland public
hospitals. Potential subjects will be given a folder contai-
ning information about the study. This includes a detailed
information sheet, an informed consent form and material
to give to their family and/or health-care provider. The
study personnel will clearly explain that because the trial is
a randomized trial, whether the patient receives a PHF is
determined by a random process. A log is kept of all pa-
tients that meet the eligibility criteria. A patient is con-
sidered to be enrolled in the study upon completion of the
informed consent process and have been randomized.
After the patient has consented, their GP will be con-
tacted by the study investigators and a time organized to
provide information about the project, demonstrate the
tools and, if a patient was randomized to the e-PHF, load
the software and authenticate the GP. After the patient
has consented, they will be interviewed and a baseline
medical history will be obtained, using their medicalrecords where available. This history includes all current
and previous medical conditions, procedures, medications
and alerts. The patient’s other health-care providers, such
as their specialists, will not be routinely contacted, except
when asked to complete a baseline health-care provider
questionnaire and for the authentication process. These
health-care providers will be approached by the participat-
ing patients during their routine appointments.
Interventions
Electronic portable health file
The e-PHF concept and software were developed to im-
plement the objectives of this study. The e-PHF is stored
on a USB flash drive (Fig. 2). Scripts for the installation
process and initiation of the antivirus software are in-
cluded at the front-end of the program The software is
written in Java, uses Eclipse [38] (an integrated develop-
ment environment) and requires a Java Runtime [39] to
execute, which in principle allows it to run on any of the
major platforms. The patient information is stored in
separate files for each patient in the form of xml files
encoded using a standard compression algorithm. The
e-PHF includes encrypted XML in an extensible schema,
with click and type interface to facilitate functions such
as doctor authentication, audit trail, non-repudiation
and saving of changes built-in and automated. The file is
read-only without the USB flash drive. Therefore the
e-PHF cannot be edited unless the USB flash drive is con-
nected to the health-care provider’s USB port with the as-
sociated audit trail. This feature provides synchronization
among all users. Software information includes audit in-
formation for each modification, including the computer
host and login name identification of the doctor and
date. The combination provides identification and non-
repudiation for the patient data, and user’s ordinary au-
thentication via the host computer operating system.
Several levels of password protection and doctor
authentication are required. The e-PHF runs from the
USB flash drive which also includes antivirus software.
The USB flash drive also carries the software allowing it
to be installed on computers of any new health-care pro-
vider once the patient has provided permission. Written
as well as online information regarding the project and
installation is provided, as well as a free 1800 telephone
support number. Information regarding the study is in-
corporated on a tag that is attached to the USB flash
drive and the 1800 telephone number is engraved onto
the USB flash drive. Self-installation is encourage to
evaluate the projects sustainability, and a record will be
kept of how many health-care providers self-installed
the software from the patient’s USB flash drive versus
having the project support team install the software.
Once the patient has securely entered their password
and the e-PHF application launches, the health-care
Fig. 2 The electronic and paper portable health files
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cated user. This requires the health-care provider to
contact the study personnel on an 1800 support number.
Once the health-care provider generates their own pass-
word, and after the study personnel authenticates the
health-care provider’s identity, the health-care provider
is given an authentication key. This authentication
process only can proceed if the USB flash drive is con-
nected to the host computer. The authentication keycreates synchronized a record of the entire e-PHF on the
host computer to allow the provider to read (but not
write to) the e-PHF record after the patient has left the
consultation, without requiring connection of the patient’s
USB flash drive. However, security is still enforced, as the
health-care provider must enter their password to launch
and read the patient’s read-only record.
If the USB flash drive is lost, the data is encrypted and
cannot be accessed without the patient’s password. A
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e-PHF, once password protocols are met, and the patient
takes the new USB flash drive to the last authenticated
user. There are a number of other features of the e-PHF,
designed to improve accuracy and acceptability, which
are not provided in this protocol.
Paper portable health file
The p-PHF was designed to implement the objectives of
the study. It is a color-coded, 280-page, A6 ring-bound
book in 39 sections that contains general information,
medical and other health-care related information. It
contains a health-care provider section in part A, and a
patient section in part B (Figs. 2 and 3). As it is paper
the book is not secured. If the book is lost, then only the
pages that were scanned at the six-monthly intervals by
the study personnel can be repopulated in another
p-PHF, unless a health-care provider or the patient has
copied the pages in the intervening period.
Trial arms
Arm one: electronic portable health file
Arm one is the e-PHF added to usual care. The e-PHF will
be kept by the subject (or caregiver) and taken to health
provider visits. At each visit the health-care provider has
the opportunity to read the contents of the e-PHF. The
health-care provider then has the opportunity to write to
the e-PHF. The information that is recorded is informa-
tion that is deemed relevant by the health-care provider. ItFig. 3 Excerpt from contents of the paper portable health filecan be a record of the entire visit or a summary of the
visit. The current visit information can subsequently be
printed, exported or copied and pasted into another file.
Information that the health-care provider believes the pa-
tient may not want disclosed to other health-care pro-
viders is discussed with the patient, and a decision is made
whether it should be recorded in the e-PHF or not. The
medical information that can be recorded includes recent
and past medical problems and conditions, examination
findings, investigations requested and their results, current
medications, medication changes, any adverse events, con-
dition management plans and clinical audits of the pro-
cesses of care derived from best practice guidelines.
Patients can also enter this information in their patient
section. Patients have access to read all sections of the e-
PHF, but can only write to the patient section.
Arm two: paper portable health file
Arm two is the p-PHF added to usual care. The p-PHF
intervention in content is similar to the electronic counter-
part, but is paper-based within an A6 spiral bound book.
Arm three: usual care
Arm three has no PHF and is usual care only.
Additional procedures
All subjects randomized to either the e-PHF or p-PHF
will receive a PHF pre-populated with a summary of
their baseline medical history, including past and current
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information is obtained after an interview with one of
the study’s medical investigators, who is a medical doc-
tor and who has access to the GP, specialist and hospital
medical records for verification. Once the PHF has been
prepared with the patient’s medical information, the pa-
tient is asked to verify that the information is correct.
Patients randomized to usual care also undergo the same
processes, but the information is not used to populate a
PHF and is kept for analysis purposes.
All patients also complete a baseline questionnaire
that includes items on demographic information, social
and lifestyle information, experience with computers,
quality-of-life information, health-care utilization, per-
ceptions about personal health files, health-care commu-
nication, health-care satisfaction and health literacy.Outcomes
Primary outcome
The primary outcome is a combined endpoint of the total
number of important clinical events, defined as: all over-
night hospitalizations, all serious out-of-hospital events
and death. Validation of hospitalizations or out-of-hospital
events occurs by subject interview, and health-care pro-
vider and hospital records as close to real time as is pos-
sible. In addition, record linkage with Medicare Australia,
Department of Veterans Affairs, Australian Institute of
Health and Welfare and NSW Health during the study is
another source of valid information on hospitalizations,
health service utilization (including a record of all medical
encounters) and deaths. Furthermore, an Independent
Adjudication Committee (IAC) determines which out-of-
hospital events are serious, and are therefore included in
the primary combined outcome.Secondary outcome
Secondary outcomes include patient interview and ques-
tionnaire self-report data on quality of life (SF-36 and
EQ-5D), and whether PHFs are acceptable in terms of
user-friendliness, convenience and usefulness to patients
and their health-care providers. Additional outcomes in-
clude adherence to management plans, duplicate investi-
gations and adverse drug reactions. Subjects will be asked
to complete questionnaires at baseline and at regular in-
tervals over the course of the trial (Table 1). The question-
naires include items on health literacy (the short Test of
Functional Health Literacy Assessment (TOFHLA) [40,
41] and the Single-Item Literacy Screener (SILS) [42]), ex-
perience with information technology, acceptability of and
satisfaction with the e-PHF or p-PHF, measures of func-
tional status (SF-36) and utility (EQ-5D), health service
utilization, all health-related events, satisfaction with med-
ical care, perception of continuity of care, and adverseevents. Additional information will be recorded from the
p-PHF and e-PHF to evaluate its real-time use.
Health-care providers will also provide information
regarding their experience with information techno-
logy, acceptability of and satisfaction with the e-PHF or
p-PHF, uptake of management plans, medication errors,
duplicative investigations, health service utilization and
adverse events by interview and questionnaire at base-
line and at 48 months.
The PHF will be retrieved from the subject at three
months and then every six months, and as per the as-
sessment schedule for collection of process measures
and clinical outcomes. The p-PHF pages are scanned
and the e-PHF data is copied. In the event of loss of the
p-PHF, a replacement notebook will be provided will be
populated using the patient’s stored information. In the
event of a lost USB flash drive, a copy of the latest file
can be retrieved from the computer of the last authenti-
cated health provider visited with their e-PHF. If a PHF
has been lost this event is documented as an adverse
event, but not a serious adverse event.
Safety, adverse events and risk assessment
An adverse event is defined in the International Conference
on Harmonisation (ICH) Guideline for Good Clinical
Practice as ‘any untoward medical occurrence in a patient
or clinical investigation subject administered a pharma-
ceutical product and that does not necessarily have a
causal relationship with this treatment’. In this trial, any
known breach of PHF security, accuracy and confiden-
tiality, whether intentional or unintentional will be con-
sidered an adverse event. A serious adverse event will be
considered to be where these breaches lead to physical or
emotional harm, as perceived by the participant. All ad-
verse events are adjudicated by the committee. Dis-
claimers are included in the p-PHF and e-PHF regarding
the medical information, and users are cautioned that
there is the possibility of error or inaccuracy. The dis-
claimer also states that the user’s professional and clinical
expertise and judgment are required at all times when
using the information contained in the PHFs. Adverse
events data, including seriousness of the adverse event, is
collected with every questionnaire and during retrievals.
Methods: assignment of interventions
Sequence generation and allocation concealment
Subjects will be randomized to one of three arms using
computer-generated random numbers. The allocation
sequence is concealed as randomization is via a central
telephone using an Interactive Voice Response System
((IVRS) maintained at a separate organization). Factors
for stratification are: aged 60 to 74 years or over 75 years;
private medical insurance or no private medical insu-
rance and hospitalization in the previous 12 months or
Table 1 Schedule of assessments
Time point (months) T0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 60 72,84
PATIENTS
Demographic information X X X X X X X X X X X X
Information technology literacy X X X X
Health literacy X X X X
Health and Lifestyle X X X X
Satisfaction with Health Care X X X X
Quality of life/SF-36 X X X X X X X X X X X X
Health Status/Utility/EQ-5D X X X X X X X X X X X X
Health care utilization X X X X X X X X X X X X
Satisfaction with Health Professional Communication X X X X
Acceptability of PHFa X X
Patient Compliance with PHFa X X X X X X X X X
Health professionals compliance with PHFa X X X X X X X X X
Hospitalizations and Deathsb X X X X X X X X X X X
Serious out-of-hospital eventsb X X X X X X X X X X X
Medications use X X X X X X X X X X X
Duplicate Investigations X X X X X X X X X X X
Adverse events X X X X X X X X X




Acceptability of PHF X
Satisfaction with Health Professional Communication X
IT experience X
Compliance with PHF by patient X
Compliance with PHF by health professionals X
Adverse events X
HEALTH PROFESSIONALS’ MEDICAL RECORDS
Comparison of PHF with health professional medical recordsd X
RECORD LINKAGE – DATABASEc
Deaths X X
Overnight Hospitalizations X X
Day Only Hospitalizations X X
Emergency Department Visits X X
Health care utilization- health professional visits X X
Health care utilization-prescription medications X X
aHealth Professional compliance will be done only for his/her patients enrolled in the trial. Subject acceptability, satisfaction and compliance will be done on all
PHF subjects. Subject compliance will be undertaken by questionnaire and when the interventions are recalled for data extraction. Control no-PHF subjects will
also be contacted and given the opportunity to discuss trial-related activities to reduce bias
bThese assessments will be elicited from the GP and other providers, from subjects or their primary health care givers in real time during the trial. It will be
validated by medical record data where possible, then adjudicated by the blinded adjudication committee
cRecord linkage with NSW State and Commonwealth databases when the last subject has exited the randomized component of the trial and again 3 years after
the last subject has exited the trial
dGP compliance evaluates data from the medical record with data recorded on the electronic PHF or in the paper PHF
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tains informed consent, the study manager calls the
IVRS and after entering the strata factors, is given the
randomly assigned intervention by the IVRS.
Blinding
Once the subject is enrolled in the trial they will be allo-
cated a unique subject identifier, which is a six-digit
number without any other identifier (subject ID). Any
further documentation associated with the subject will
only be identified by this number. Only persons directly
related with this trial will have access to the database or
stored records. The nature of the intervention does not
permit blinding of either trial participants or health-care
providers. Therefore, there will be potential for bias in
trial conduct and potential for ascertainment bias in the
determination of important clinical outcomes and qua-
lity of life. To reduce clinical outcome ascertainment
bias, a blinded IAC will be used to make the deter-
mination which out-of-hospital events are serious. The
other primary outcomes, mortality and all overnight
hospitalizations, are objective outcomes and are not
subject to ascertainment bias. Data on all hospitali-
zations, same-day hospitalizations, 28-day readmissions
and deaths are administrative outcomes, coded and col-
lected by the clinical information systems of public and
private hospitals within the state of NSW. Question-
naires that collect information on secondary outcomes
are mailed to all trial subjects without any assignment
identifiers. All statistical analyses unrelated to accept-
ability of PHF and compliance of use are masked to
intervention allocation via a separate data set.
Methods: statistical analysis plan
All analyses will include all subjects randomized regard-
less of whether or when they may have withdrawn from
the study. Therefore, for the primary and secondary
objectives, the analysis will follow intention-to-treat
principles. However, a completer’s analysis which is a
comparison based on random allocation of subjects with
complete data at the end of the trial, will also be under-
taken as well as an as-treated complier’s analysis, which
is based on the actual intervention and for how long it
was utilized. The completer’s analysis and the as-treated
analyses are exploratory analyses only.
Hypotheses
The primary hypothesis is that addition of a patient-held
PHF to usual care results in fewer important clinical
events using a combined endpoint of deaths, overnight
hospitalizations and serious out-of-hospital events com-
pared to usual care. The secondary hypothesis is that
addition of a patient-held PHF to usual care improves
quality of life and health status.Primary statistical analyses
There are two co-primary analyses because this is a
three-arm, randomized controlled trial: e-PHF versus
usual care and p-PHF versus usual care. Both analyses
use the combined endpoint of deaths, hospitalizations
(excluding day-only admissions) and adjudicated serious
out-of-hospital events, and both use an adaptation of
the Andersen-Gill formulation [43] of the proportional
hazards model in order to capture possibly correlated
events in the same subject. A robust variance estimate
[44] will be used that takes into account the possibility
of correlation of risk of multiple events within a subject
by including an additional time-dependent covariate in-
dicating whether the event was the first or subsequent
event of its kind. The level of significance for each ana-
lysis is 0.025. This is an intention-to-treat analysis.
Secondary analyses
Secondary analyses with be comparison of quality of life
and health status, and incremental cost per quality-
adjusted life-year with confidence interval by Fieller’s the-
orem [45, 46]. In analysis of quality of life, missing data
will be addressed by imputation with sensitivity analysis.
Other analyses (exploratory)
1. Analyses as for the primary analysis but adjusted for
study completion after 48 months of treatment
(completers analysis);
2. Analyses as for the primary analysis but adjusted
for study completion after 48 months of treatment
and adherence with interventions (compliers
analysis);
3. Subgroup analysis of each of the composite
endpoints: hospitalizations, serious out-of-hospital
events and deaths;
4. Subgroup analysis of day-only hospitalizations;
5. Analysis of patient acceptability;
6. Analysis of health-care provider acceptability;
7. Qualitative exit interviews and
8. Subgroup analyses of primary and secondary
endpoints adjusted by covariates: age, health
literacy, comorbidity status and computer and
information technology literacy.
Additional analyses
9. Health service utilization and health-care costs;
10. Medication errors, duplicative investigations;
11. Clinical workflow;
12. Management plans uptake and documentation;
13. Health literacy;
14. Information technology and computer expertise and
15. Adverse events.
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Hospitalizations are likely to dominate events in the
composite endpoint of hospitalizations (excluding day-
only hospitalizations), serious out-of-hospital events and
deaths. Therefore hospitalization data were used to
power the study, with the aim to detect a 25 % reduction
in hospitalizations. The sample size and power calcula-
tions for the study were based on the Fisher’s exact test,
as this is a conservative analysis and enables use of the
Australian Institute of Health and Welfare data (AIHW)
[47] that indicate a yearly risk of hospitalization of 62 %
for women and 78 % for men aged 66 to 69, and 80 %
and 115 % for women and men aged 70 to 74, respec-
tively, using hospital separation data from 2003 to 2004.
The AIHW data are for all hospitalizations. This study
excludes day-only hospitalizations in the composite end-
point, but includes serious out-of-hospital events and
deaths. Overall, we estimated that at least 70 % of the
subjects in the control arm would have at least one
event (either an overnight hospitalization, a serious out-
of-hospital event or death) throughout the 48-month
duration of the trial. With these assumptions, 80 %
power and a 0.025 level of significance, to detect a 25 %
reduction in hospitalizations requires 158 subjects per
arm for analysis by a Fisher’s exact test of proportions.
In order to provide for the loss of power due to patients
discontinuing (at the most conservative, assuming a
40 % non-differential dropout from the intervention
arms), the trial requires 792 subjects, or 264 subjects
per arm. Regarding local feasibility, in 2008 there were
11,421 unplanned admissions via the emergency de-
partment at our institution (St George Hospital) alone
for patients aged 60 years or older. The entire study
area of southern Sydney has several public and private
hospitals.Ethics and governance
Informed consent will be obtained from each participant.
The project has been approved by the South Eastern
Sydney Local Health District Human Research Ethics
Committee - Southern Sector (EC00135) reference num-
ber: 06/124 Lassere (approval letter dated 8 December
2006). A recent amendment was approved (2 September
2014) to conduct exit interviews to obtain further quali-
tative data regarding the project. An IAC that includes a
neurologist, a cardiologist, a rheumatologist and an in-
fectious disease physician will evaluate all reported ser-
ious out-of-hospital events to determine whether they
consider the event was a serious out-of-hospital event.
All adjudications are undertaken blind to randomized
arm status. The committee includes the Chief Investiga-
tor (ML) and project manager (SB) for administrative
purposes only.Discussion
The PHF protocol is, to our knowledge, the first example
of a randomized study of an electronic assist to medical re-
cords that tests whether use improves the rate of important
patient-relevant outcomes, overnight hospitalizations and
deaths (plus medically important out-of-hospital events,
anticipated to be rare). This framing of the hypothesis (re-
duction in hospitalizations and deaths) is crucial because
past experience has not infrequently found that clinical
studies using intermediary clinical outcomes or biomarkers
often mislead when tested in subsequent outcome studies
[48]. Our use of patient-relevant outcomes is of further
importance given the extensive enthusiasm surrounding
expected gains offered by contemporary information tech-
nology. A pivotal study in this area must be firmly based in
unequivocally convincing outcomes. Additionally, what is
needed is not only a test of the e-PHF compared to usual
care, but to anchor this result with a p-PHF result for com-
parison; thus, we employ a three-arm design.
When we designed this study, there was substantial
disenchantment with ‘big brother’ perceptions surroun-
ding medical records stored centrally or in web-based
systems, sentiments reflected in feedback in our pilot
study and indicated by the failure of HealthConnect in
Australia and similar systems elsewhere. Thus, we made
the decision to empower the patient by having him or
her be the holder of their PHF; it is the patient’s respon-
sibility to take the PHF to their respective providers. In
parallel, we canvass a very large portion of GPs in the
relevant areas to solicit their participation. Implicit in
this design is the need for compliance by both patients
and providers in following the protocol. We entertained
a fourth study arm, a web-based portal, but could not pur-
sue this opportunity because of additional costs involved
in terms of both web-based expertise and increasing trial
size to accommodate additional comparisons.
Strictly masked treatment allocation (by remote
computer) is employed. A variety of trial conduct features
were used to limit bias present because full blinding was
not feasible in this trial. Firstly, the primary endpoint was
made objective (overnight hospitalization and death) and
will be ascertained regardless of whether a patient has
withdrawn from the study. Medically important serious
out-of-hospital events are expected to be rare and will all
be independently adjudicated. Because the most important
secondary endpoint, quality of life, may be prone to ascer-
tainment bias, we were particularly attentive to balancing
patient interactions and contact across all three arms re-
garding the six-monthly data collection through question-
naires of quality-of-life measures, PHF acceptability and
health service utilization, and periodic telephone inquiries
to confirm events such as hospitalizations, out-of-hospital
events and adverse events that may need adjudication. We
are also attempting to obtain post-discontinuation quality-
Lassere et al. Trials  (2015) 16:253 Page 13 of 16of-life measures and interviews in patients choosing to
drop out of the trial. Although study personnel clearly ex-
plain that the study is a randomized trial and whether the
patient receives a PHF or not is determined by a random
process, patients may nonetheless agree to be recruited
hoping to be randomized to a PHF arm, and later with-
draw consent and drop out of the trial if they are rando-
mized to usual care.
Possibly, a tendency to better health attention gene-
rally for the patients in the PHF arms could skew the
hospitalization rate in either direction. However, merely
undertaking this trial will yield a wealth of experience
with the electronic assists to medical records, including
a cross-section of older patients with multiple comor-
bidities, and high-end consumers of health services and
their acceptance to carrying their medical information,
their interactions with health-care professionals and sys-
tems and how to study this. Finally, it is recognized that
any clear result, whether positive or negative, from this
trial will provide hypotheses for the future, as the tech-
nology used will be antiquated in a short time.
It is recognized that studies of this size are underpo-
wered to detect mortality differences alone. AIHW data
[47] show a mortality rate of 0.95 % and 1.68 % for women
aged 65 to 69 and 70 to 74, respectively. The data for men
are 1.72 % and 2.90 %, respectively. Assuming a population
of equal women and men and equal 65 to 69 and 70 to 74
age groups, the four-year mortality rate is 7.25 %. To detect
a 25 % mortality reduction, assuming 80 % power and a
0.05 level of significance, 2,947 subjects per arm would be
needed. The study could not recruit these numbers; there-
fore the trial was designed with a composite endpoint of
overnight hospitalizations, serious out-of-hospital eventsFig. 4 Pragmatic-explanatory continuum indicator summary of the COMMUand death as its primary endpoint. Neither endpoint on its
own would have sufficient power for a subgroup analysis.
Our sample size calculation was based on hospital se-
paration data from 2003 to 2004, which was the most re-
cent data available at the time we first planned the study.
Hospital separation data from 2007 to 2008 showed an in-
crease in overall separations to public hospitals of between
12.9 % and 28.8 % for those aged 65 years and older.
Randomized trials have previously been described as
either primarily efficacy trials or primarily effectiveness
trials. Schwartz and Lellouch in 1967 [49] described
these two design approaches as explanatory or pragmatic
trials. Generally, interventions are first evaluated under
ideal conditions to evaluate a causal question and ensure
internal validity of the results. However, these interven-
tions are shown not to be applicable in the real-world
setting: they are said to lack external validity, otherwise
known as generalizability. Effectiveness or pragmatic trials
attempt to address this gap, and recently the Consolidated
Standards of Reporting Trials (CONSORT) statement has
been extended [50] to improve the reporting of pragmatic
trials. Two tools have been developed to help trial de-
signers: the Pragmatic-Explanatory Continuum Indicator
Summary (PRECIS) tool [51] and the Reach, Effectiveness,
Adoption, Implementation and Maintenance (RE-AIM)
framework [52].
Pragmatic studies of PHRs are generally non-randomized
[53] or employ cluster randomization [54], options that
simplify the study and possibly improve participant adhe-
rence, but risk explanatory validity. In our study we have
attempted to balance efficacy and effectiveness, and using
the PRECIS tool, we provide a summary of where our trial
sits on the Pragmatic-Explanatory Continuum (Fig. 4).NICATE trial
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likely to be responsive to the intervention as these are
higher risk individuals because they are older and have
more comorbidities, but there are few exclusions in that
all such individuals are enrolled unless life expectancy is
less than 12 months and there are cognitive or psychiatric
reasons why consent informed cannot be provided. There
is some flexibility regarding how the practitioners in the
experimental and comparison arms apply the inter-
ventions or practice usual care. No minimum criteria are
set except that the patient’s GP must have access to a
Windows computer during the consultation, and that at
least one of the specialist health-care providers also has
access to a Windows computer. The primary barrier is
that practitioners that use Apple products and software,
or Linux operating systems cannot take part.
There is formal follow-up of participants to determine
serious out-of-hospital events and obtain quality of life
and other data, but the primary endpoint is a composite
endpoint of hospitalizations (excluding day only), deaths
and serious out-of-hospital events, and the former two
are obtained from administrative registries. The study
has been designed so that the primary outcome is cli-
nically important to patients, caregivers, health-care
providers and other health care-related personnel. Par-
ticipant compliance to the prescribed intervention and
practitioner adherence to the protocol are both unobtru-
sive, although they are measureable at the end of the trial.
The primary analysis includes all patients regardless of
compliance and practitioner adherence, so that a determin-
ation of whether the intervention works under usual condi-
tions is determined. Unlike many other health-care system
pragmatic trials, which are cluster randomized, we made a
decision to randomize individual patients to the interven-
tion, which provides a greater causal relationship and is
more in keeping with an explanatory trial in our setting.
There is considerable evidence that patients like the
PHF, believe it is useful and feel more in control of their
care when they have access to it. These are important out-
comes. The fundamental question is whether use of a PHF
is acceptable enough short term to enable demonstration
translation into important patient outcomes. It may well
be that in the near term, physician visits and even hospi-
talizations may increase due to attention to aspects of
chronic diseases previously overlooked. One mechanism
by which we believe access to a PHF will result in changes
to patient outcomes and processes involves the use of
multiple medications among an older patient population
with complex health problems. However, the important
question is whether a PHF and any accompanying in-
crease in intensity of care will translate into later benefits
in morbidity, as measured by significant hospitalizations,
which is probably the most feasible overall capture of
morbidity. Only with a properly designed trial usingrandomization can one obtain a valid demonstration of a
reduction in morbidity and in mortality. However, to date
this has not been easy to demonstrate, and successful
demonstration may vary with exactly what benefit is being
considered and, as importantly, what time course is being
used. Our proposal addresses both trial duration and size
in a randomized setting with important clinical outcomes.
Trial status
The COMMUNICATE trial began patient recruitment
in March 2010 and we anticipate that recruitment will
be completed in September 2015.
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